SPIRIT III JAPAN Versus SPIRIT III USA: A Comparative Intravascular Ultrasound Analysis of the Everolimus-Eluting Stent

American Journal of Cardiology

Volumn 106, Issue 1, 2010, Pages 13-17

  Shimohama, Takao ^a   Ako, Junya ^a   Yamasaki, Masao ^a   Otake, Hiromasa ^a   Tsujino, Ichizo ^a   Hasegawa, Takao ^a   Nakatani, Daisaku ^a   Sakurai, Ryota ^a   Chang, Hyeonsoo ^a   Kusano, Hajime ^b   Waseda, Katsuhisa ^a   Honda, Yasuhiro ^a   Stone, Gregg W ^c   Saito, Shigeru ^d   Fitzgerald, Peter J ^a   Sudhir, Krishnankutty ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b ABBOTT VASCULAR   (United States)

^c Howard Hughes Medical Institute   (United States)

^d SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSECTION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; INTIMA; INTRAVASCULAR ULTRASOUND; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UNITED STATES;

AGED; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; ULTRASONOGRAPHY, INTERVENTIONAL; UNITED STATES;

EID: 77953595565     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.02.008     Document Type: Article

References (16)

1. Fujii K., Carlier S.G., Mintz G.S., Yang Y.M., Moussa I., Weisz G., Dangas G., Mehran R., Lansky A.J., Kreps E.M., Collins M., Stone G.W., Moses J.W., and Leon M.B. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 45 (2005) 995-998
2. Sonoda S., Morino Y., Ako J., Terashima M., Hassan A.H., Bonneau H.N., Leon M.B., Moses J.W., Yock P.G., Honda Y., Kuntz R.E., and Fitzgerald P.J. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol 43 (2004) 1959-1963
3. Kimura T., Morimoto T., Nakagawa Y., Tamura T., Kadota K., Yasumoto H., Nishikawa H., Hiasa Y., Muramatsu T., Meguro T., Inoue N., Honda H., Hayashi Y., Miyazaki S., Oshima S., Honda T., Shiode N., Namura M., Sone T., Nobuyoshi M., Kita T., and Mitsudo K. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 119 (2009) 987-995
4. Stone G.W., Midei M., Newman W., Sanz M., Hermiller J.B., Williams J., Farhat N., Mahaffey K.W., Cutlip D.E., Fitzgerald P.J., Sood P., Su X., and Lansky A.J. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299 (2008) 1903-1913
5. Ako J., Morino Y., Honda Y., Hassan A., Sonoda S., Yock P.G., Leon M.B., Moses J.W., Bonneau H.N., and Fitzgerald P.J. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol 46 (2005) 1002-1005
6. Kataoka T., Grube E., Honda Y., Morino Y., Hur S.H., Bonneau H.N., Colombo A., Di Mario C., Guagliumi G., Hauptmann K.E., Pitney M.R., Lansky A.J., Stertzer S.H., Yock P.G., and Fitzgerald P.J. 7-Hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 106 (2002) 1788-1793
7. Kimura M., Mintz G.S., Carlier S., Takebayashi H., Fujii K., Sano K., Yasuda T., Costa R.A., Costa Jr. J.R., Quen J., Tanaka K., Lui J., Weisz G., Moussa I., Dangas G., Mehran R., Lansky A.J., Kreps E.M., Collins M., Stone G.W., Moses J.W., and Leon M.B. Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound. Am J Cardiol 98 (2006) 436-442
8. Gerber R., and Colombo A. Does IVUS guidance of coronary interventions affect outcome?. A prime example of the failure of randomized clinical trials. Catheter Cardiovasc Interv 71 (2008) 646-654
9. Uren N.G., Schwarzacher S.P., Metz J.A., Lee D.P., Honda Y., Yeung A.C., Fitzgerald P.J., and Yock P.G. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur Heart J 23 (2002) 124-132
10. Kim Y.S., Koo B.K., Seo J.B., Park K.W., Suh J.W., Lee H.Y., Park J.S., Kang H.J., Cho Y.S., Chung W.Y., Chae I.H., Choi D.J., Kim H.S., Oh B.H., and Park Y.B. The incidence and predictors of postprocedural incomplete stent apposition after angiographically successful drug-eluting stent implantation. Catheter Cardiovasc Interv 74 (2009) 58-63
11. Tanabe K., Serruys P.W., Degertekin M., Grube E., Guagliumi G., Urbaszek W., Bonnier J., Lablanche J.M., Siminiak T., Nordrehaug J., Figulla H., Drzewiecki J., Banning A., Hauptmann K., Dudek D., Bruining N., Hamers R., Hoye A., Ligthart J.M., Disco C., Koglin J., Russell M.E., and Colombo A. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation 111 (2005) 900-905
12. Weissman N.J., Koglin J., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., Kutcher M., Wong S.C., Strickland W., Mooney M., Russell M.E., Ellis S.G., and Stone G.W. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1201-1205
13. Sakurai R., Hongo Y., Yamasaki M., Honda Y., Bonneau H.N., Yock P.G., Cutlip D., Popma J.J., Zimetbaum P., Fajadet J., Kuntz R.E., Wijns W., and Fitzgerald P.J. Detailed intravascular ultrasound analysis of zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol 100 (2007) 818-823
14. Miyazawa A., Ako J., Hongo Y., Hur S.H., Tsujino I., Courtney B.K., Hassan A.H., Kandzari D.E., Honda Y., and Fitzgerald P.J. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am Heart J 155 (2008) 108-113
15. Waseda K., Miyazawa A., Ako J., Hasegawa T., Tsujino I., Sakurai R., Yock P.G., Honda Y., Kandzari D.E., Leon M.B., and Fitzgerald P.J. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv 2 (2009) 779-784
16. Hoffmann R., Mintz G.S., Mehran R., Kent K.M., Pichard A.D., Satler L.F., and Leon M.B. Tissue proliferation within and surrounding Palmaz-Schatz stents is dependent on the aggressiveness of stent implantation technique. Am J Cardiol 83 (1999) 1170-1174